<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523964</url>
  </required_header>
  <id_info>
    <org_study_id>CMD-001</org_study_id>
    <nct_id>NCT01523964</nct_id>
  </id_info>
  <brief_title>DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls</brief_title>
  <official_title>A Phase I, Multi-Center, Controlled, Prospective Correlative Study of Electrical Impedance Myography in Males With Duchenne Muscular Dystrophy and In Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dart Therapeutics. LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dart Therapeutics. LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Physicians seek a method to assess neuromuscular disease that is both non-invasive and
      quantifiable. Many patients do not tolerate standard current day assessment tools (such as
      needle electromyogram), and Electrical Impedance Myography (EIM) has the potential to serve
      as a non-invasive, quantifiable, diagnostic tool for neuromuscular disease. If successful,
      these devices will allow for improved ability to diagnose neuromuscular disease and to assess
      disease progression or remission, allowing for better care of individual patients as well as
      for use in clinical trials, where improved outcome measures for neuromuscular diseases is
      being sought.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy subjects and subjects with DMD will be screened during Visit 1. Screening evaluations
      will establish eligibility and will include a medical history, abbreviated physical
      examination, vital signs (blood pressure, temperature, pulse, and respirations), and weight.
      Eligible subjects will provide assent, as stipulated by Institutional Review Board (IRB)
      requirements, and a parent/guardian will sign an informed consent, after which the subject
      will be considered enrolled.

      Subjects will be enrolled into 4 study cohorts for a total of approximately 90 subjects.
      Allocation into these cohorts is planned due to considerations regarding the effect of age on
      outcomes.

      Visit 2, Study Assessments, may take place on the day of Visit 1 screening evaluations. If
      the subject cannot complete study assessments on the same day, the subject may return and
      complete Visit 2 evaluations within approximately 24 hours of the end of Visit 1.

      Visit 2 assessments will include morphological testing of muscle length and girth, skin fat
      measurement, Clinical Assessments (6-Minute Walk Test [6MWT], North Star Ambulatory
      Assessment, timed function tests, dynamometry), and 3 phases of Device Performance testing.
      Phase 1 Device Performance testing will be done by each of 2 trained raters (Rater A and
      Rater B) from the research site, designated to perform the Device Performance testing on all
      subjects at their respective site. At least 10 minutes after completion of the first
      assessments, Phase 2 Device Performance testing will be repeated by Rater A. Upon completion
      of the Phase 2 Device Performance testing, the subjects will proceed with Clinical
      Assessments performed by a physical therapist. Following Clinical Assessments, Phase 3 Device
      Performance testing will be performed by Rater B.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With an Adverse Event.</measure>
    <time_frame>1 day</time_frame>
    <description>Adverse events will be assessed during the time the subject is enrolled in the trial.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>DMD subject ages 3-7 inclusive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Young DMD Testing with EIM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMD subject ages 8-12 inclusive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Older DMD Testing with EIM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control ages 3-7 inclusive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Young Healthy Testing with EIM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control ages 8-12 inclusive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Older Healthy Testing with EIM</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Testing with EIM</intervention_name>
    <arm_group_label>DMD subject ages 3-7 inclusive</arm_group_label>
    <arm_group_label>DMD subject ages 8-12 inclusive</arm_group_label>
    <arm_group_label>Healthy Control ages 3-7 inclusive</arm_group_label>
    <arm_group_label>Healthy Control ages 8-12 inclusive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DMD Subject Cohorts

          -  Male subjects

          -  Subjects with a chronologic age of 3 to 7 years inclusive for Cohort A, and 8 to 12
             years inclusive for Cohort B

          -  Subjects with DMD diagnosed with mutational testing and/or absence of dystrophin on
             muscle biopsy

          -  Subjects with proximal pelvic girdle weakness (Gower's maneuver, difficulty with
             arising from floor and going up steps)

          -  Subjects who can walk 10 meters unassisted (ie, without braces, canes, or other aids)

          -  Subjects who are taking systemic corticosteroids and/or any other medication which, in
             the judgment of the investigator, could impact muscle strength or physical activity
             levels, must be on a stable dose for at least 4 weeks prior to initiation of study
             measurements

          -  Subjects who provide assent, as stipulated by IRB requirements, and whose
             parent/guardian signs an informed consent form

          -  Subjects who are willing and able to cooperate and comply with all protocol
             requirements and procedures

        Healthy Control Cohort

          -  Healthy males with normal neuromuscular examination

          -  Subjects with a chronologic age of 3 to 7 years inclusive for Cohort C, and 8 to 12
             years inclusive for Cohort D

          -  Subjects who provide assent, as stipulated by IRB requirements, and whose
             parent/guardian signs an informed consent form

          -  Subjects who are willing and able to cooperate and comply with all protocol
             requirements and procedures

        Exclusion Criteria:

          -  Subjects with daytime ventilatory dependence (non-invasive or tracheostomy)

          -  Subjects enrolled in a DMD therapeutic clinical trial concomitantly or within the past
             4 weeks

          -  Subjects with any physical or mental condition which may, in the investigator's
             opinion, render the subject unable to complete the tasks of the study appropriately
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massauchusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <results_first_submitted>August 9, 2013</results_first_submitted>
  <results_first_submitted_qc>October 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2013</results_first_posted>
  <last_update_submitted>October 16, 2013</last_update_submitted>
  <last_update_submitted_qc>October 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>EIM</keyword>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>electrical impedance myography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was from February 2012 to August 2013. Subjects know to the site staff were approached during clinic visits or by telephone to ascertain interest. In addition, referrals from message posted on DMD website were included if they met protocol criteria.</recruitment_details>
      <pre_assignment_details>There were no significant events. Subjects were screened for eligibility and enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DMD Subject Ages 3-7 Inclusive</title>
        </group>
        <group group_id="P2">
          <title>DMD Subject Ages 8-12 Inclusive</title>
        </group>
        <group group_id="P3">
          <title>Healthy Control Ages 3-7 Inclusive</title>
        </group>
        <group group_id="P4">
          <title>Healthy Control Ages 8-12 Inclusive</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DMD Subject Ages 3-7 Inclusive</title>
        </group>
        <group group_id="B2">
          <title>DMD Subject Ages 8-12 Inclusive</title>
        </group>
        <group group_id="B3">
          <title>Healthy Control Ages 3-7 Inclusive</title>
        </group>
        <group group_id="B4">
          <title>Healthy Control Ages 8-12 Inclusive</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With an Adverse Event.</title>
        <description>Adverse events will be assessed during the time the subject is enrolled in the trial.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DMD Subject Ages 3-7 Inclusive</title>
          </group>
          <group group_id="O2">
            <title>DMD Subject Ages 8-12 Inclusive</title>
          </group>
          <group group_id="O3">
            <title>Healthy Control Ages 3-7 Inclusive</title>
          </group>
          <group group_id="O4">
            <title>Healthy Control Ages 8-12 Inclusive</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an Adverse Event.</title>
          <description>Adverse events will be assessed during the time the subject is enrolled in the trial.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day (length of subject participation)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DMD Subject Ages 3-7 Inclusive</title>
        </group>
        <group group_id="E2">
          <title>DMD Subject Ages 8-12 Inclusive</title>
        </group>
        <group group_id="E3">
          <title>Healthy Control Ages 3-7 Inclusive</title>
        </group>
        <group group_id="E4">
          <title>Healthy Control Ages 8-12 Inclusive</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>scab on left ankle abrasion dislodged</sub_title>
                <description>Subject has prior left ankle abrasion with scab. During 6 minute walk scab was dislodged during a fall.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Operating Officer</name_or_title>
      <organization>DART Therapeutics</organization>
      <phone>415-341-5783</phone>
      <email>egoldstein@dartrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

